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Abstract 
The α7 nicotinic acetylcholine receptors (nAChRs) have been highlighted as a target 
for cognitive enhancement in schizophrenia. Adult female hooded-Lister rats received 
sub-chronic PCP (2 mg/kg) or vehicle i.p. twice daily for seven days, followed by 7-
days washout.  PCP-treated rats then received PNU-120596 (10 mg/kg; s.c.) or saline 
and were tested in the attentional set-shifting task.  Sub-chronic PCP produced a 
significant cognitive deficit in the extra-dimensional shift (EDS) phase of the task 
(P<0.001, compared with vehicle).  PNU-120596 significantly improved performance 
of PCP-treated rats in the EDS phase of the attentional set-shifting task (P<0.001).  In 
conclusion, these data demonstrate that PNU-120596 improves cognitive dysfunction 
in our animal model of cognitive dysfunction in schizophrenia, most likely via 
modulation of α7 nACh receptors.   
 
Keywords:  Cognition, Schizophrenia, Attentional set-shifting; α7 nACh receptors; 
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Introduction 
Cognitive deficits in schizophrenia have an important impact on outcome for patients 
and remain largely untreated by current medication (Keefe et al., 2007).  There is thus 
a clear need for improvements in therapy of this aspect of the illness. We have 
demonstrated robust impairments in set-shifting ability measured by impaired 
performance in the IED task using the CANTAB in first episode psychosis patients 
(Saleem et al., 2010).  This task assesses rule acquisition and reversal learning, based 
on visual discrimination of shapes and lines.  Our results are supported by other 
studies showing that patients with schizophrenia show impaired set-shifting ability 
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(Haut et al., 1996; Kolb and Wilshaw, 1983; Pantelis et al., 1999).  The rodent 
version of the attentional set-shifting task was adapted by Birrell and Brown (2000) 
and is a useful analogue of the Wisconsin Card Sorting Test (Berg, 1948).  The 
TURNS initiative has determined that this rodent test can be used in preclinical tests 
to evaluate new therapeutic strategies (www.turns.ucla.edu).  Initial studies using the 
perceptual attentional set-shifting task showed that lesions of the medial prefrontal 
cortex (mPFC) produce a selective deficit in the extra-dimensional shift (EDS) phase 
(Birrell and Brown, 2000).  In our laboratory we have shown a selective deficit in 
female rats in the EDS phase following our 7 day sub-chronic phencyclidine (PCP) 
treatment regime; this deficit was attenuated by clozapine and risperidone, but was 
unaffected by haloperidol (McLean et al., 2008).  This PCP model in female rats has 
been found to induce robust cognitive deficits and neurobiological changes of 
relevance to schizophrenia and shows efficacy of a range of novel targets (see Neill et 
al., 2010 for review).  
The most prevalent nicotinic acetylcholine receptors (nAChRs) are the α4β2 
and α7 subtypes, both of which show reduced numbers in schizophrenia (Freedman et 
al., 1995; Breese et al., 2000).  Both of these receptor subtypes play a role in 
cognitive processing (Chan et al., 2007; Gray and Roth, 2007; Schreiber et al., 2002). 
See Leiser et al., 2009 for a recent review of the role of α7 nAChRs in cognitive 
processing of relevance to schizophrenia.   We have recently shown that the α7 
nAChR full agonist, PNU-282987, reverses a sub-chronic PCP-induced deficit in two 
cognitive tests; novel object recognition and operant reversal learning (McLean et al., 
2011).  It has been suggested that full nicotinic receptor agonists may provide sub-
optimal benefits due to sustained activation and/or desensitisation at the target 
receptor (Quick and Lester, 2002; Smith et al., 2002; Harris et al., 2004; White and 
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Levin, 2004); this dilemma poses a pharmacological problem with respect to long-
term therapy.  However, we showed that the full α7 nAChR agonist, PNU-282987, 
was effective in reversing the PCP-induced deficit in novel object recognition 
following once daily administration for 15 days, suggesting that repeated activation of 
the target over a 15 day period does not evoke tolerance.  However, this is relatively 
short-term and does not necessarily reflect the clinical situation, in which patients 
may have received a specific treatment for months or years.   
An alternative approach to enhance α7 nAChR function is by augmenting 
effects of acetylcholine (ACh) via positive allosteric modulation (PAM) that can 
reinforce the endogenous cholinergic tone without directly activating α7 nAChRs (see 
Maelicke, 2000).  Various molecules have been reported to positively modulate α7 
nAChRs, including PNU-120596 (Hurst et al., 2005), ivermectin (Krause et al., 1998) 
and galantamine (Zhao et al., 2006).  PNU-120596 represents a novel positive 
allosteric modulator at the α7 nAChRs, which can increase the maximal agonist-
evoked current and slow the decay of the currents in the continued presence of an 
agonist.  The aim of this study was to investigate the efficacy of the selective α7 
nAChR positive allosteric modulator, PNU-120596, in a model of relevance to 
cognitive deficits in schizophrenia, specifically PCP-induced deficits in the perceptual 
attentional set-shifting task. 
 
Materials and Methods 
Subjects and housing conditions 
Thirty adult female hooded-Lister rats (Harlan, UK) housed in groups of five were 
used as subjects.  Animals initially weighing 200-220 g were maintained under 
standard laboratory conditions at a temperature of 21°C (±2°C) and humidity of 40–
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50%.  They were maintained on a 12 h/12 h light/dark cycle (lights on at 0700 h) and 
experimental procedures were performed during the light phase.  Rats were gradually 
food deprived to approximately 90% of free-feeding body weight; reduced body 
weight was maintained by restricting the amount of food (standard laboratory chow, 
Special Diet Services, Essex, UK) given to each rat per day (12 g/day).  The 
availability of water was not restricted.  Experiments were conducted in accordance 
with the Animals (Scientific Procedures) Act UK (1986), and approved by the 
University of Bradford ethical review process. 
 
Attentional set-shifting 
Rats were trained and tested in the attentional set-shifting procedure as described in 
detail in McLean et al. (2008), except rats were counterbalanced equally on odour and 
digging medium initially in simple discrimination.  In all cases, rats were tested in the 
attentional set-shifting procedure 24 h after training.  The first stage of testing was the 
SD, which was identical to the SD in the training session on the previous day, except 
new exemplars were used.  Testing continued until the rat reached a criterion of six 
consecutive correct responses.  For the compound discrimination (CD), a second 
dimension was introduced (odour or medium), but the correct and incorrect exemplars 
remained the same.  For the reversals, the exemplars and relevant dimensions 
remained the same, but the rats had to learn that the previously baited odour was now 
incorrect and the other odour was now the correct one.  New exemplars were used for 
the ID and ED shifts.  The specific exemplars used are shown in Table 1; odours were 
aromatic oils (Bodyshop, UK) and were selected based on a pilot study showing that 
the oils used did not induce aversive behaviours.  For the ED shift, the previously 
irrelevant parameter (odour or medium) was now relevant.   
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Drugs 
Rats were pre-treated with 2.0 mg/kg PCP or vehicle (0.9% saline) by the 
intraperitoneal (i.p.) route twice daily for seven days.  Dosing with sub-chronic PCP 
or vehicle was followed by a washout period of a further seven days.  PCP 
hydrochloride (Sigma, UK) was dissolved in 0.9% saline.  PCP-treated rats were then 
administered either PNU-120596 (supplied by Johnson and Johnson, Beerse, Belgium) 
or vehicle (PBS + 5% DMSO + 5% solutol) 30 min prior to testing.  All treatment 
groups were n=10.  PNU-120596 (N-[5-chloro-2,4-dimethoxyphenyl]-N'-[5-methyl-3-
isoxazo lyl]-urea) was dissolved in PBS containing 5% DMSO (Sigma, UK) and 5% 
solutol (Johnson and Johnson, Beerse, Belgium), and was given in 1 ml/kg volume via 
the s.c. route and tested at one dose only of 10 mg/kg.  The dose was selected based 
on efficacy to reverse a sub-chronic PCP deficit in the novel object recognition task in 
our laboratory, which tested doses of 5, 10 and 20 mg/kg of PNU-120596 and showed 
greatest efficacy at 10 mg/kg and some efficacy at 20 mg/kg (Idris et al, unpublished 
observations).  
 
Pharmacokinetics analysis 
The plasma and brain pharmacokinetics of PNU-120596 were studied in satellite 
groups of female hooded-Lister rats (~200 g).  The compound was administered at 10 
mg/kg as reported above, using the same formulation and dose volume as the main 
pharmacological studies. From each individual animal, (n=3), blood and brain 
samples were collected at 15 and 30 min, 1, 2, 4, 7 and 24 h after dose administration. 
Samples were placed immediately on melting ice and plasma was obtained following 
centrifugation at 4C for 10 min at 1900 x g.  Tissue samples were homogenized in 
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water (1/9 w/v or + 3 ml if tissue weight <0.33 g).  All samples were shielded from 
daylight and stored at  -18C prior to analysis.  Plasma and brain samples were 
analysed using an LC-MS/MS method with a lower limit of quantification (LLOQ) of 
1.0 ng/ml in both matrices.  A limited pharmacokinetic analysis was performed using 
WinNonlin Professional (Version 5.1).  
 
Data and statistical analysis 
Data for trials to criterion were analysed by a repeated measures two-way ANOVA 
using phase as a within-subjects factor and drug treatment as between-subjects factor 
and post-hoc Bonferroni multiple comparisons test.  Post-hoc paired t-tests were 
carried out to compare difficulty between phases within the same treatment group. 
 
Results 
Attentional set-shifting 
A repeated measures two-way ANOVA using phase as a within-subjects factor and 
drug treatment as between-subjects factor revealed a significant effect of phase [F6,162 
= 33.23; P<0.001], a significant effect of drug [F2,27 = 11.01; P<0.001] and an overall 
significant interaction [F2,27 = 6.59; P<0.01].  A significant increase in trials to 
criterion in reversal 1 was observed in all treatment groups compared to simple 
discrimination (P<0.01; fig 1).  A significant increase (P<0.05) was also observed in 
the vehicle group in the EDS phase compared to the IDS phase, indicating that an 
attentional set had been formed.  Post-hoc analysis within the treatment groups 
showed that PCP significantly increased trials to criterion in the EDS phase (P<0.001) 
and in reversal 3 (P<0.01).  This deficit was significantly attenuated in the EDS phase 
by PNU-120596 (10 mg/kg, s.c.; P<0.001).  There was no effect of treatment on time 
8 
 
taken to complete the trials (data not shown), suggesting there were no motoric effects 
of the compound. 
 
Active plasma and brain levels 
Following s.c. administration of 10 mg/kg PNU-120596 to female hooded-Lister rats, 
rather low mean plasma levels were observed (Cmax 14.5 ng/ml,) at 0.8 h post dose.  
As can be seen in fig 2 and table 2, plasma levels were low yet relatively stable across 
the first 4 hours post dose.  Area under the concentration time curve (AUC0-last) was 
167 ng.h/ml. As the compound was administered as a suspension, dissolution at the 
s.c. injection site was probably rather slow and incomplete.  Brain levels were 
consistent with plasma indicating a rapid absorption and subsequent distribution 
(brain/plasma ratio ~1).  
 
Discussion 
The current study showed that sub-chronic PCP induced a robust cognitive deficit in 
attentional set-shifting, and the α7 nAChR positive allosteric modulator, PNU-120596, 
selectively attenuated the deficit in the EDS phase of the attentional set-shifting task.  
Recent studies in our laboratory and elsewhere show that many targets are effective to 
improve the PCP-induced deficit in a variety of tasks assessing different aspects of 
cognitive function (see Neill et al., 2010 and Jones et al., 2011 for recent reviews). 
For example, in novel object recognition (NOR): several atypical antipsychotics, a D1 
receptor agonist, ampakines, glycine uptake inhibitors, 5-HT2A receptor inverse 
agonists, a 5-HT6 receptor antagonist, GABAA receptor agonists and full agonists at 
α7 nACh receptors are active to reverse the PCP-induced deficit (see Neill et al., 2010 
for further details).  Clearly, the key question here is which, if any, are effective in the 
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clinic and how valuable the positive animal data are.  Inspection of the clinical trials 
on-going at schizophreniaresearchforum.org shows that many of these targets are 
currently in various stages of clinical testing, with varying degrees of success, with 
patients not always assessed for cognitive function.  It is therefore still early to 
correlate pre-clinical with clinical efficacy, although some data are emerging.  For 
animal models, it will be important to show efficacy across a range of cognitive 
domains, in more than one model (e.g. in a genetic and pharmacological and/or 
neurodevelopmental model) to show that efficacy is maintained following chronic 
treatment and also demonstrate effects on neurobiological measures such as gamma 
oscillations and parvalbumin.  
The present results show that the vehicle-treated group required significantly 
fewer trials to reach criterion in the IDS phase than in the EDS phase, suggesting that 
an attentional set was formed.  In all treatment groups, rats required more trials to 
reach criterion in reversal 1 compared to the SD stage of the task, suggesting that all 
groups found reversal 1 more difficult than the previous stages.  There was a 
significant increase in trials required to reach criterion in PCP-treated rats in the EDS 
stage, suggesting that sub-chronic PCP causes a deficit in attentional set-shifting 
ability.  This is in agreement with a previous study in our laboratory (McLean et al., 
2008).  This deficit in also seen in patients with schizophrenia and in our first episode 
study (Saleem et al., 2010), strengthening the validity of this model in rats.  This 
result is supported by several studies in other laboratories in which sub-chronic PCP 
also produces deficits in the EDS phase of the attentional set-shifting task, although 
ours is the only study to use female rats (Rodefer et al., 2005; 2008; Goetghebeur and 
Dias, 2009; Egerton et al., 2008).  In the current study PNU-120596 (10 mg/kg) 
significantly reversed this PCP-induced deficit in the EDS phase.  In addition, PCP 
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significantly increased trials to criterion in reversal 3.  Although PNU-120596 did not 
significantly improve the PCP-induced deficit in reversal 3, the number of trials was 
decreased from 13.3 to 9.9, a level of responding similar to that of the vehicle-treated 
group i.e. 8.5 trials.  PK analysis revealed that PNU-120596 at 10 mg/kg reached 
plasma and brain, albeit at relatively low levels.  Ideally the PK analysis should have 
been carried out in satellite PCP-treated rats rather than drug naive rats.  However, as 
the dose of PCP is low and is followed by a 7 day washout period, it is unlikely to 
affect the clearance mechanisms of the compound.   
Based on an in vitro calcium flux assay (data not shown), the compound 
shows activity on the human α7 ion channel with an EC50 of 0.16 µM (50 ng/ml). 
Data for the rodent ion channel is not available so the assumption is that the activity is 
comparable across species.  In vivo a Cmax of 14.8 ng/ml (0.05 µM) and an AUC 0-last 
of 167 ng.h/ml (0.53 µM.h) were observed.  The concentrations observed in vivo are 
therefore within the range for in vitro activity (assumption human/rat as above).  At 
this point we do not fully understand the PK/PD relationship of this molecule or 
mechanism, i.e. a maximum plasma concentration or an AUC driving the response. 
Further studies are clearly required to elucidate the full PK/PD profile and will be the 
subject of further studies.   
In support of our data, a recent study found the α7 nAChR partial agonist, 
RG3487, improved sub-chronic PCP-induced deficits in attentional set-shifting in 
male Long-Evans rats (Wallace et al., 2011).  In addition, nicotine was found to 
improve auditory and visual shift trials in male Sprague-Dawley rats (Brown et al., 
2010).  An α7 nAChR full agonist, compound A ((R)-N-(1-azabicyclo[2.2.2]oct-3-
yl)(5-(2-pyridyl)thiophene-2-carboxamide), has also been shown to improve olfactory 
working memory in the odour span task in uncompromised rats (Rushforth et al., 
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2010).  We have also found the full agonist, PNU-282987, to reverse sub-chronic 
PCP-induced deficits in the novel object recognition task (McLean et al., 2011).  For 
a detailed review of the effects of nicotine in animal models of attention see Levin et 
al., (2011). 
Positive allosteric modulators (PAMs) of α7 nAChRs have been classified as 
either type 1 or type 2 compounds; type 1 compounds predominantly affect the peak 
current response, whereas type 2 compounds affect both peak current responses and 
the kinetics of agonist-evoked responses (Bertrand and Gopalakrishnan, 2007).  It has 
been shown that PNU-120596 causes potentiation of agonist-evoked α7 receptor 
responses by binding within the nAChR transmembrane region, therefore 
characterising it as a type 2 PAM (Young et al., 2008).  The attenuating effects of 
PNU-120596 in our cognitive task are supported by a study showing that PNU-
120596 increased the potency of ACh by ~10-fold and reversed an amphetamine-
induced deficit in auditory gating in rats (Hurst et al., 2005).  PNU-120596 has also 
been reported to enhance the increase in dopamine release in the mPFC induced by 
choline and an α7 nAChR agonist (compound A; (R)-N-(1-azabicyclo[2.2.2]oct-3-
yl)(5-(2-pyridyl)thiophene-2-carboxamide); it was also shown that PNU-120596 (1 
mg/kg; s.c.) when administered systemically (but not locally) also produced an 
increase in dopamine overflow in the mPFC in the absence of an agonist (Livingstone 
et al., 2009).  This is of importance as it has been previously shown that attentional 
set-shifting performance is dependent upon the mPFC (Birrell and Brown, 2000) and 
that dopamine plays a pivotal role in cognition (Goldman-Rakic et al., 2004).  Indeed, 
we have found the PCP-induced deficit in novel object recognition memory is 
accompanied by impaired dopamine neurotransmission in the PFC during the 
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retention trial of the task (Snigdha et al., 2008).  This result was also recently 
confirmed in a second study in our laboratory (McLean, unpublished observations). 
In conclusion, PNU-120596 reversed a sub-chronic PCP-induced deficit in 
attentional set-shifting ability.  To our knowledge this is the first study to investigate 
an α7 nAChR PAM in the attentional set-shifting task.  It is suggested from other 
studies that these compounds may exert their cognitive enhancing effects by 
potentiating the effects of endogenous acetylcholine and increasing levels of 
dopamine and acetylcholine in the prefrontal cortex.  
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Tables and Figures 
 
Table 1:  Specific exemplars used (presented in pairs) 
 
Dimension Pairing 1 (CD) Pairing 2 (IDS) Pairing 3 (EDS) 
Odour Rose = O1 
White flower = O2 
Green Meadow = O3 
Coconut = O4 
Orange = O5 
Almond = O6 
Medium 
 
Wood shavings = M1 
Cat litter = M2 
Small pebbles = M3 
Aspen = M4 
Fine sawdust = M5 
Wood blocks = M6 
 
 
 
Table 2:  Individual and mean plasma concentrations and some basic 
pharmacokinetic parameters after single s.c. administration at 10 mg/kg of PNU-
120596 in female hooded-Lister rats.   
Exposure in rat after subcutaneous administration of PNU-120596 
 
B1 B2 B3 
mean 
SC 
  s.d. 
Body Weights (g) 195 196 186 192 ± 5 
Time (h)     Plasma levels (ng/ml) Plasma levels (ng/ml) 
0.25 15.8 12.1 10.7 12.9 ± 2.6 
0.5 19.8 12.6 10.6 14.3 ± 4.8 
1 18.3 12.7 11.1 14.0 ± 3.8 
2 19.1 12.6 9.03 13.6 ± 5.1 
4 15.8 11.8 10.8 12.8 ± 2.6 
7 10.4 9.00 8.13 9.18 ± 1.15 
24 2.59 1.97 1.77 2.11 ± 0.43 
Cmax (ng/ml) 19.8 12.7 11.1 14.5 ± 4.6 
Tmax (h) 0.5 1.0 1.0 0.8 ± 0.3 
t1/2 (h) 7.9 7.7 7.7 7.8 ± 0.1 
time points t1/2 4-24 4-24 4-24    
AUC0-last (ng.h/ml) 204 158 138 167 ± 34 
last time point AUC 24 24 24    
AUC0-inf (ng.h/ml) 233 180 158 190 ± 39 
MRT (h) 11.6 11.7 11.9 11.7 ± 0.2 
 
 
 
 
 
 
21 
 
 
Figure 1 
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Legends 
 
Table 1: Specific exemplars used in each phase of the attentional set-shifting task.  Odours 
were applied around the rims of digging bowls which were filled with various digging media 
depending upon the phase being tested.  The significance of pairing within a test phase 
ensures that, for example, rose is always accompanied with white flower within a test trial [O 
= Odour, M = Medium]. 
 
Table 2: Individual (animals B1, B2, B3) and mean plasma concentrations (ng/ml) and some 
basic pharmacokinetic parameters after single s.c. administration at 10 mg/kg of PNU-120596 
in female hooded-Lister rats.  Plasma (and brain) samples were collected at different time 
intervals after compound administration.  Concentrations of PNU-120596 were determined as 
described in materials and methods and plotted as a function of time. 
 
Figure 1:  The effect of acute treatment with PNU-120596 (10 mg/kg, s.c.) in sub-chronic 
PCP (2 mg/kg, twice daily for 7 days, i.p.) treated rats on total trials to reach criterion in the 
attentional set-shifting task.  All data are expressed as mean ± SEM (n=10).  Data were 
analysed by repeated two-way ANOVA and post-hoc Bonferroni multiple comparisons test.  
$
P<0.05-
$$
P<0.01; significant increase in trials to criterion between stages of the task analysed 
by a post-hoc paired t-tests.   **P<0.01-***P<0.001; significant increase in trials to criterion 
in PCP-treated rats.  
###
P<0.001; significant decrease in trials to criterion in PNU-120596-
treated rats.   
 
Figure 2: Mean plasma concentrations of PNU-120596 after s.c. administration at 10 mg/kg 
in female hooded-Lister rats.  Plasma (and brain) was collected at different time intervals after 
compound administration.   
 
